Pantoprazol Zentiva (Pantoprazole Sodium Sesquihydrate)

Pantoprazole Sodium Sesquihydrate, the active ingredient in Pantoprazol Zentiva, is a proton pump inhibitor presented as an injectable solution for intravenous use. It treats acid‑related disorders such as GERD, erosive esophagitis and Zollinger‑Ellison syndrome in hospital settings. GNH USA supplies Pantoprazol Zentiva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

GNH USA supplies Pantoprazol Zentiva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Pantoprazol Zentiva is a proton pump inhibitor indicated for several acid‑related conditions.

- Gastroesophageal reflux disease (GERD): reduces gastric acid exposure and promotes healing of esophageal irritation. - Erosive esophagitis: accelerates ulcer resolution and prevents further mucosal damage. - Zollinger‑Ellison syndrome: controls excessive gastric acid secretion associated with gastrin‑producing tumors. - Prevention of NSAID‑induced gastric ulcers: lowers the risk of ulcer formation in patients receiving non‑steroidal anti‑inflammatory drugs. - Pre‑operative preparation: reduces gastric acidity before surgical procedures to minimise aspiration risk.

Pantoprazol Zentiva may cause adverse reactions, most of which are mild and reversible.

Common Side Effects: - Headache: mild to moderate intensity. - Diarrhea: watery stools without blood. - Nausea: occasional feeling of queasiness. - Abdominal pain: cramp‑like discomfort. - Flatulence: increased intestinal gas. - Injection site reactions: redness or mild swelling at the IV site.

Serious or Rare Side Effects: - Severe hypersensitivity: rash, itching, swelling, or anaphylaxis. - Clostridioides difficile infection: persistent watery diarrhea with abdominal pain. - Acute interstitial nephritis: sudden decrease in urine output, flank pain. - Hepatotoxicity: elevated liver enzymes, jaundice. - Thromboembolic events: unexplained leg swelling or chest pain. - Osteoporosis‑related fractures: hip or vertebral fractures with long‑term use.

Before initiating therapy with Pantoprazol Zentiva, consider the following precautions.

- Renal impairment: adjust monitoring if creatinine clearance is reduced. - Hepatic impairment: use with caution in patients with liver disease. - Long‑term therapy: assess need for calcium and vitamin D supplementation to mitigate bone loss. - Concomitant antibiotics: monitor for increased risk of Clostridioides difficile infection. - Pregnancy and lactation: evaluate risk‑benefit ratio as safety data are limited. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Pantoprazol Zentiva can affect the pharmacokinetics of several co‑administered medicines.

Major Interactions (Avoid): - Ketoconazole oral suspension: markedly reduced absorption; avoid concurrent use. - Atazanavir: decreased plasma concentrations; avoid co‑administration.

Moderate Interactions (Monitor Closely): - Warfarin: potential increase in INR; monitor coagulation parameters. - Digoxin: possible rise in serum levels; check renal function and drug levels. - Methotrexate (high dose): reduced clearance; monitor for toxicity. - Clopidogrel: diminished antiplatelet effect; consider alternative therapy.